TULIP ReTrain Study
Condition(s) studied
Investigational drug(s) / intervention(s)
Multiparametric ultrasound with contrast (Sonovue and Optison): Participants will receive 3D mpUS using both Sonovue and Optison contrast agents during a single transrectal imaging session.
Study summary
This prospective clinical study aims to retrain and validate the PCaVision AI algorithm for the detection and localization of clinically significant prostate cancer (csPCa) using multiparametric ultrasound (mpUS) with two different ultrasound contrast agents: Sonovue and Optison. Data will be collected using a commercial version of the LOGIQ E10 ultrasound machine, with full histopathological correlation in patients undergoing radical prostatectomy.
Eligibility
Primary outcome measure(s)
- Sensitivity and Specificity of PCaVision Algorithm (Sonovue and Optison) Compared to Histopathology — From baseline imaging to histopathology report (typically within 2-4 weeks post-surgery)
Sensitivity and specificity of the PCaVision algorithm in detecting and localizing clinically significant prostate cancer (csPCa, Gleason Grade Group ≥2) at the voxel level, based on 3D multiparametric ultrasound (mpUS) images using Sonovue and Optison, validated against full prostate histology after radical prostatectomy.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Amsterdam UMC | Amsterdam | Netherlands |
More Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials in the Netherlands
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06974539 on ClinicalTrials.gov ↗ ← All trials in the Netherlands